

Resource Summary Report

Generated by [NIF](#) on Jul 30, 2026

Purified Mouse IgG2b, ? Isotype Ctrl

RRID:AB_2744505

Type: Antibody

Proper Citation

BioLegend Cat# 401201, RRID:AB_2744505

Antibody Information

URL: http://antibodyregistry.org/AB_2744505

Proper Citation: BioLegend Cat# 401201, RRID:AB_2744505

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, ICFC, WB, IP, ICC, IHC, FA, ChIP

Antibody Name: Purified Mouse IgG2b, ? Isotype Ctrl

Description: This monoclonal targets

Clone ID: clone MG2b-57

Antibody ID: AB_2744505

Vendor: BioLegend

Catalog Number: 401201

Alternative Catalog Numbers: 401202

Record Creation Time: 20250819T235810+0000

Record Last Update: 20250820T065829+0000

Ratings and Alerts

No rating or validation information has been found for Purified Mouse IgG2b, ? Isotype Ctrl.

Warning: Discontinued at BioLegend

Applications: FC, ICFC, WB, IP, ICC, IHC, FA, ChIP

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Li YR, et al. (2025) Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells. Cell reports. Medicine, 6(9), 102321.

Brown ME, et al. (2025) Human Stem Cell-Derived γ -cells Expressing An Optimized CD155 Reduce Cytotoxic Immune Cell Function for Application in Type 1 Diabetes. bioRxiv : the preprint server for biology.

Fonseca D, et al. (2024) TRIM65 regulates innate immune signaling by enhancing K6-linked ubiquitination of IRF3 and its chromatin recruitment. Cell reports, 43(12), 114960.

Li YR, et al. (2023) Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design. iScience, 26(10), 107952.

Li YR, et al. (2022) Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers. iScience, 25(9), 104859.

Bonavita E, et al. (2020) Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade. Immunity, 53(6), 1215.